HCG at a Glance

• Human chorionic gonadotropin is a heterodimeric glycoprotein hormone not a synthetic peptide. It consists of a 92-residue α subunit shared with LH, FSH and TSH and a 145-residue β subunit that confers all of its receptor specificity held together non-covalently.
• It is an agonist at the luteinising hormone/choriogonadotropin receptor (LHCGR) the same receptor as LH, but with a circulating half-life roughly an order of magnitude longer, a difference produced almost entirely by its carbohydrate not its protein.
• It is produced by placental syncytiotrophoblast, sustains the corpus luteum in early pregnancy, and is the analyte every pregnancy test detects.
• The recombinant versus urinary-derived distinction is central to any research listing: both exist as approved prescription products, they are not identical in glycoform, and they are quantified differently.
• Approved prescription products containing hCG exist for ovulation induction, for selected hypogonadotropic hypogonadism in males and for prepubertal cryptorchidism. A research-grade vial is not one of them.
• hCG is an established tumour marker in gestational trophoblastic disease and germ cell tumours, and the long-discredited “HCG diet” has been the subject of explicit FDA and FTC enforcement. Research material is research-use-only.

What Is Human Chorionic Gonadotropin?

hCG belongs to the glycoprotein hormone family alongside luteinising hormone (LH), follicle-stimulating hormone (FSH) and thyroid-stimulating hormone (TSH). All four are heterodimers of a common α subunit and a hormone-specific β subunit, and all four are extensively glycosylated. PubChem catalogues it under Human Chorionic Gonadotropin, though the entry makes a general point: a heterogeneously glycosylated heterodimer of roughly 36–40 kDa is not well described by a small-molecule record, and its identity rests on sequence, subunit pairing and glycan profile rather than a formula.

The α subunit is 92 amino acids and common to all four hormones encoded by a single gene. It carries two N-linked glycans and contributes to receptor binding but confers no specificity whatsoever; free α subunit is biologically inert.

The β subunit is 145 amino acids and is where the specificity lives. Over its first 114 residues it is approximately 80–85% identical to LHβ, which is why the two hormones share a receptor. The difference that matters is at the other end: hCGβ carries a 24-residue C-terminal peptide extension absent from LHβ, bearing four O-linked glycans in addition to the subunit’s two N-linked sites.

That extension is the single most consequential structural feature of the molecule. Its heavily sialylated O-linked glycans resist hepatic clearance, giving a circulating half-life measured in tens of hours against roughly twenty to thirty minutes for LH. Same receptor, same signalling, vastly different duration of exposure, produced by carbohydrate rather than protein, and useful enough that the C-terminal peptide has since been grafted onto other gonadotropins specifically to extend their half-lives.

The subunits are held together non-covalently each stabilised internally by a cystine-knot motif. Dissociation into free α and free β abolishes biological activity, which is the central fact governing how the material must be handled.

How Does HCG Work?

LHCGR and Two Ligands for One Receptor

The luteinising hormone/choriogonadotropin receptor is a class A G-protein-coupled receptor with an unusually large leucine-rich-repeat extracellular domain, which is where the hormone binds. It is expressed on ovarian theca and granulosa cells, the corpus luteum and testicular Leydig cells. Structural and molecular studies of hCG and its receptor were reviewed from the late 1990s (PMID 9769716), and the model has been stable since: the heterodimer engages the extracellular domain, and that engagement is transmitted to the transmembrane bundle to activate G protein.

The receptor couples principally to Gs raising cAMP and activating PKA; at higher occupancy it also recruits Gq/phospholipase C. PKA drives phosphorylation of StAR the rate-limiting step in delivering cholesterol to the inner mitochondrial membrane, and transcription of the steroidogenic enzyme cascade. The output is steroidogenesis.

Two ligands, one receptor. LH provides the pulsatile physiological signal; hCG the sustained pregnancy signal. Because hCG occupies the receptor far longer per molecule it produces a qualitatively different stimulus, which is exactly why it is used clinically as an ovulation trigger, a single sustained pulse standing in for the endogenous LH surge.

Placental Biology and the Pregnancy Test

hCG is synthesised by syncytiotrophoblast. Its first job is luteal rescue: in a non-conception cycle the corpus luteum regresses and progesterone falls; in a conception cycle, hCG from the implanting embryo sustains it until the placenta takes over steroidogenesis at around 8–10 weeks. Serum concentrations rise steeply through the first trimester, peak around weeks 8–11 and decline to a plateau.

Because hCG is produced by trophoblast and essentially nothing else in a non-pregnant, non-neoplastic adult, it is close to an ideal biomarker. Every pregnancy test is an immunoassay for it, and home tests target the β subunit precisely because an assay directed at the shared α subunit would cross-react with LH, FSH and TSH.

The molecular reality is more complicated than “hCG” suggests. Cole’s review of the biology and detection of the hormone (PMC2649930) describes multiple independent variants in circulation, regular hCG, hyperglycosylated hCG free β subunit and degradation forms including the β core fragment in urine, with different structures and different biological roles. Hyperglycosylated hCG, produced by invasive cytotrophoblast, is associated with implantation and trophoblastic malignancy rather than luteal support. Immunoassays differ in which forms they detect, which is why hCG results are method-dependent and why assay choice matters in oncology.

Glycosylation Is Part of the Pharmacology

For most peptides in a research catalogue, sequence is identity. For hCG it is not. The glycans determine folding and subunit assembly, protect the dimer from proteolysis, and, through terminal sialylation govern clearance. Desialylated glycoprotein hormone is cleared rapidly by the hepatic asialoglycoprotein receptor, so a preparation with the correct sequence but altered sialylation has a different half-life and a different in vivo potency.

This is why hCG is quantified in International Units of biological activity rather than milligrams of protein: a mass-based specification cannot capture a property that depends on glycan structure. It is also why any hCG preparation offering only a mass figure, with no bioactivity assignment, is under-specified for quantitative work.

Research Evidence and the Regulatory Record

Recombinant Versus Urinary-Derived Material

Urinary-derived hCG is purified from the urine of pregnant donors. Pregnyl is described in its FDA labelling as obtained from the urine of pregnant persons, supplied as a sterile dried powder for intramuscular injection after reconstitution and standardised in USP units (FDA label, NDA 017692). Because the starting material is a biological fluid, such preparations contain co-purified urinary proteins.

Recombinant hCG is expressed in a characterised cell line. Ovidrel (choriogonadotropin alfa) is described in its labelling as two non-covalently linked subunits of 92 and 145 amino acids, a water-soluble glycoprotein with carbohydrate attached at multiple sites on both (FDA label, NDA 021149). The labelling makes the comparison explicit: the α chain is structurally identical to that of urinary hCG, the β chain and its glycosylation are very similar, and the glycoform patterns differ, mainly in the branching and sialylation of the oligosaccharides. Recombinant material is presented by protein mass rather than in units.

That sentence in an approved label is the clearest available statement of what separates the two sources: the protein is the same, the sugars are not quite. A Cochrane review comparing recombinant with urinary hCG for final oocyte maturation triggering in IVF and ICSI cycles (PMID 27106604, PMC7133782) did not find evidence that one is clearly superior on the principal outcomes. The distinction remains important for a different reason: identity, consistency and the meaning of a stated quantity all differ, and a research listing that does not say which it is has omitted the most informative fact about the material.

Approved Clinical Uses, as Regulatory Record

Approved prescription hCG products exist, and reporting what they are licensed for is a statement about the regulatory record, not guidance of any kind. The approved indications on the urinary product’s labelling are three: prepubertal cryptorchidism not due to anatomical obstruction; selected cases of hypogonadotropic hypogonadism in males; and induction of ovulation and pregnancy in anovulatory infertile women in whom anovulation is not due to primary ovarian failure, following appropriate gonadotropin therapy. The recombinant product’s approved indication is narrower: final follicular maturation and early luteinisation in women undergoing assisted reproductive technology or ovulation induction.

The common thread is LHCGR agonism in three settings, driving a testis to descend, substituting for absent pituitary LH drive, and standing in for the endogenous LH surge: one mechanism, three clinical problems, all under prescription supervision in manufactured products with approved specifications.

A research-grade vial is not one of those products. It has no marketing authorisation, no approved labelling, no approved route, no regulated sterility or endotoxin specification and no assigned potency verified against a regulatory standard. The existence of approved products makes that distinction sharper, not softer, because it creates an obvious temptation to read approved-product framing onto unregulated material.

hCG as a Tumour Marker

The oncological role is well established and is where the assay literature is most demanding.

hCG is secreted by gestational trophoblastic disease hydatidiform mole, invasive mole, choriocarcinoma, placental site trophoblastic tumour, and by germ cell tumours of testis and ovary, where it is measured alongside AFP and LDH for diagnosis, staging and response monitoring.

The measurement problem is that “hCG” is a family. A study comparing total hCG with the free β subunit as a diagnostic marker in gestational trophoblastic disease concluded that total hCG is the more suitable measurand (PMC10661586), and a broader evaluation of commercial quantitative hCG immunoassays as tumour markers in trophoblastic and non-trophoblastic disease (PMID 37205831) examined how differently those assays behave. Assays optimised for pregnancy detection are not necessarily fit for oncological monitoring, because they may under-detect hyperglycosylated forms, free β or degradation products, which is why a laboratory working with hCG needs to know which analyte its method measures.

The “HCG Diet” and the FDA’s Action

This belongs in the record as regulatory history, and the record is unambiguous.

In the 1950s a physician working in Rome proposed hCG injection combined with a severely restricted diet as an obesity treatment. Controlled evaluation did not support it. A double-blind, placebo-controlled trial of hCG and weight loss (PMID 2405506) found no benefit attributable to the hormone, and a criteria-based meta-analysis of the randomised literature (Lijesen and colleagues, British Journal of Clinical Pharmacology, 1995; abstracted in the NHS DARE database) concluded that there is no scientific evidence hCG is effective in the treatment of obesity, that it does not bring about weight loss or fat redistribution, and that it does not reduce hunger or induce a feeling of well-being. Any weight lost on such a regimen is attributable to the caloric restriction accompanying it.

The FDA’s position is stated plainly: there are no FDA-approved hCG products for weight loss and hCG has not been demonstrated to be effective adjunctive therapy in the treatment of obesity (FDA, Questions and Answers on HCG Products for Weight Loss). Approved prescription hCG products are required to carry labelling to that effect. In December 2011 the FDA and the Federal Trade Commission jointly issued warning letters to seven companies marketing unapproved over-the-counter hCG products labelled as “homeopathic” for weight loss, on the basis that they were unapproved new drugs and misbranded drugs making unsubstantiated claims; the agency’s consumer guidance on the topic remains published (FDA, Avoid Dangerous HCG Diet Products).

For a research audience the lesson is methodological: a compound with real, well-characterised pharmacology at a known receptor, marketed for an indication in which that receptor has no plausible role, with an uncontrolled co-intervention doing all the observed work.

What Remains Unknown

Whether glycoform differences have consequences outside the trigger setting. The comparative trials examined a single high-dose ovulation trigger; whether the two preparations behave identically under repeated or lower-dose administration elsewhere is not established.

The full functional taxonomy of circulating hCG variants. Hyperglycosylated hCG, free β and the degradation forms have distinguishable biology, and how much each contributes to a measured “hCG” value in a given assay is method-specific and incompletely mapped. Separately, LHCGR transcripts have been reported outside the gonads, and the significance of that expression remains contested.

Comparison: hCG, HMG and GnRH Agonists

Three interventions act on the same reproductive axis at three different levels, and they are routinely confused.

There is a direct link between the first two columns. Human menopausal gonadotropin is purified from postmenopausal urine and standardised for both FSH and LH activity, and a substantial part of that stated LH activity in commercial preparations has been shown to derive from hCG rather than LH (PMID 8513939). Menopur, the current US menotropin product, carries an initial US approval date of 1975 (FDA label, NDA 021663). A catalogue listing HMG alongside hCG is listing two preparations whose activities overlap by design, a reason to control them separately rather than treat them as alternatives.

GnRH agonists sit one level up and produce the opposite net effect after their initial flare, since continuous receptor occupancy downregulates the pituitary. An experiment that confuses a gonadal-level agonist with a pituitary-level agent has confounded the axis it is trying to study.

Handling and Reconstitution of a Glycoprotein Hormone

This is where hCG differs most sharply from the small synthetic peptides shelved beside it. A five-residue peptide such as Ipamorelin has no tertiary structure to lose; hCG is a folded, disulphide-stabilised, non-covalently associated heterodimer whose activity depends entirely on that architecture surviving.

The dimer can dissociate. α and β are held together non-covalently, not by a disulphide bond. Heat, extremes of pH, shear and air–liquid interfaces all promote dissociation, and free α and free β are biologically inactive. A preparation can retain every amino acid it started with and have lost most of its activity.

Surface denaturation is the dominant loss route. Proteins adsorb to air–water and solid–liquid interfaces and unfold there. Shaking a reconstituted glycoprotein vial is a reliable way to inactivate it and visible foam indicates denaturation that has already occurred. The approved urinary product’s labelling instructs the user to agitate gently until dissolved and explicitly says do not shake present because it is necessary, not as a formality.

Activity is defined in units, not milligrams. Urinary products are standardised in USP or International Units of bioactivity. A research vial labelled only in milligrams carries no information about potency, and no mass-to-unit conversion is valid across preparations, because the relationship depends on glycoform and purity.

Repeated freeze-thaw is worse for a glycoprotein than for a small peptide. Each cycle concentrates solutes at the advancing ice front and creates new interfaces, both of which drive dissociation and aggregation, so aliquoting at the point of reconstitution is not optional here.

Reconstitution follows the sequence used for any lyophilised biologic. Allow the vial to reach room temperature before opening so condensation does not form on a cold cake; disinfect the septum with 70% isopropyl alcohol and let it dry; introduce the diluent slowly, down the inner wall of the vial never jetting it onto the cake. Swirl or roll gently until fully dissolved; never shake. The approved urinary product’s labelling describes exactly this, including equalising pressure with sterile air before transferring diluent.

Where a vial is entered repeatedly, a preserved monographed diluent is the conventional choice, and bacteriostatic water listed alongside research compounds at NextGenPeps, or an equivalent Bacteriostatic Water for Injection, USP product, is what most protocols specify. The approved urinary hCG product is itself supplied with a benzyl-alcohol-preserved diluent, which is why its reconstituted solution carries a 60-day refrigerated stability statement; unpreserved diluent does not support that. Two caveats belong in the record: benzyl alcohol is not inert toward proteins, so a single-entry analytical preparation is better served by unpreserved sterile water; and Bacteriostatic Water for Injection is contraindicated in neonatal use because of benzyl alcohol toxicity, a restriction carried on the approved hCG labelling itself, which states that the supplied solvent is not for use in newborns.

Store reconstituted solution refrigerated at 2–8 °C, protected from light, and do not freeze it. Record the concentration in the units the material was supplied in, and log the diluent lot alongside the hormone lot.

Is Research-Grade HCG FDA Approved?

This question needs a more careful answer for hCG than for most research compounds, and the careful answer is: prescription products containing this hormone exist, and research-grade hCG is not one of them.

Approved products include urinary-derived chorionic gonadotropin for injection, USP and recombinant choriogonadotropin alfa, each with approved labelling, approved indications, an approved route, an assigned potency and regulated manufacturing. Those approvals attach to specific manufactured products not to the molecule in the abstract.

A vial sold to a laboratory as research-grade hCG has none of that: no marketing authorisation, no approved labelling, no approved indication, no regulated manufacturing or sterility standard, no endotoxin specification, and frequently no potency assignment traceable to an international standard at all. For a biologic that last gap is more serious than it would be for a synthetic peptide, because bioactivity cannot be inferred from mass or from a chromatogram.

Two further points belong in the record. There are no FDA-approved hCG products for weight loss and the agency has taken enforcement action against products marketed for that purpose. And hCG is prohibited in male athletes at all times under the World Anti-Doping Agency Prohibited List; anyone in a tested environment should consult the current list directly.

Where to Source Research-Grade HCG

Because nothing regulatory underwrites laboratory material, and because a glycoprotein’s identity is not established by sequence alone, the documentation standard here is higher than for a synthetic peptide. A defensible record contains:

• A lot-matched certificate of analysis tied to the specific lot shipped, not a representative batch.
• A stated source, recombinant or urinary-derived, with the expression system or donor-material provenance named.
• An assigned potency in International or USP units with the standard it was calibrated against. For a preparation given only in milligrams, no potency statement exists.
• Evidence of dimer integrity such as size-exclusion chromatography or a non-reducing electrophoretic method. A reducing SDS-PAGE gel separates the subunits by design and says nothing about whether the intact heterodimer was present.
• Purity and endotoxin data appropriate to a protein not a small-molecule HPLC trace alone, and, for urinary-derived material, a statement about co-purified urinary protein burden.
• Cold-chain shipping and light-protective packaging and explicit research-use-only labelling with no suggested protocol, dosing guidance or human-use framing anywhere in the listing.

Red flags are mostly absences and overreaches. A certificate with no laboratory name, test date or lot reference is decoration rather than evidence. A supplier who will not say whether the material is recombinant or urinary has not described the product. And for this molecule specifically, any listing that borrows an approved product’s indication, brand name or clinical framing, or references weight loss in any form, should be read as a compliance failure rather than a marketing flourish, given the federal enforcement history attached to exactly that claim. A catalogue that lists HCG as a research compound can be assessed against these criteria: lot-matched analysis, declared source, assigned potency, evidence of dimer integrity, endotoxin data, cold-chain handling, and research-use-only labelling with no protocol content attached.

Frequently Asked Questions

Is hCG a peptide?

Not in the sense the word is usually used in a research catalogue. It is a heterodimeric glycoprotein hormone of roughly 36–40 kDa, two polypeptide chains of 92 and 145 residues held together non-covalently, each extensively glycosylated. Its activity depends on folding, on the subunits remaining associated and on its carbohydrate, none of which applies to a small synthetic peptide.

Why does the β subunit matter so much?

Because it carries all the specificity. The α subunit is identical across hCG, LH, FSH and TSH, so an assay directed at α cannot distinguish them. The β subunit determines which receptor the dimer engages, and its 24-residue C-terminal extension with four O-linked sialylated glycans gives hCG a half-life measured in tens of hours against roughly twenty to thirty minutes for LH.

What is the difference between recombinant and urinary hCG?

Source and glycoform. Urinary product is purified from the urine of pregnant donors and standardised in units of bioactivity; recombinant product is expressed in a characterised cell line and presented by protein mass. Per the recombinant product’s approved labelling, the α chain is structurally identical to that of urinary hCG, the β chain and its glycosylation are very similar, and glycoform patterns differ mainly in the branching and sialylation of the oligosaccharides.

Why is hCG measured in units rather than milligrams?

Because its in vivo potency depends on glycan structure, particularly sialylation, and not only on how much protein is present. Two preparations with identical amino acid content and different sialylation have different clearance and different biological effect, so a mass figure alone does not specify activity. Urinary products are standardised by bioassay in USP or International Units for that reason.

What is hCG approved for?

Approved US labelling for urinary chorionic gonadotropin lists prepubertal cryptorchidism not due to anatomical obstruction, selected cases of hypogonadotropic hypogonadism in males, and induction of ovulation and pregnancy in anovulatory infertile women in whom anovulation is not due to primary ovarian failure. Recombinant choriogonadotropin alfa is approved for final follicular maturation and early luteinisation. These are statements of the regulatory record, not guidance, and they apply to approved prescription products under medical supervision rather than to research material.

Does the HCG diet work?

No. A double-blind placebo-controlled trial found no benefit attributable to the hormone, and a criteria-based meta-analysis of the randomised literature concluded there is no scientific evidence that hCG is effective in the treatment of obesity, that it does not cause weight loss or fat redistribution, and that it does not reduce hunger. The FDA states that there are no FDA-approved hCG products for weight loss, requires approved products to carry labelling to that effect, and acted jointly with the FTC against marketers of unapproved “homeopathic” hCG weight-loss products.

The Bottom Line

hCG is the most structurally complex compound on a typical research shelf, and almost every practical question about it follows from that complexity. It is a heterodimer, so it can come apart, and when it does it stops working while still containing every amino acid it started with. It is a glycoprotein, so its identity is not captured by sequence and its potency is not captured by mass, which is why it is standardised in units of bioactivity, and why the recombinant-versus-urinary distinction is a real pharmaceutical question with a precise answer sitting in an approved product’s label. And it unfolds at interfaces, so handling instructions that read as fussy for a small peptide are load-bearing here.

The pharmacology is settled. hCG is an LHCGR agonist, functionally an LH surrogate with a much longer duration of action supplied by the sialylated C-terminal extension of its β subunit, one mechanism accounting for luteal rescue, for all three approved indications and for its use as an ovulation trigger. Its value as a pregnancy and tumour marker follows from its trophoblastic origin, with the caveat that “hCG” is a family and different assays measure different members of it.

The regulatory picture is unusually sharp. Approved prescription products exist in both forms, with approved indications, assigned potencies and regulated manufacturing; a research-grade vial has none of those things, and for a biologic that gap is wider than for a synthetic peptide. And in the one area where hCG has been most aggressively marketed to the public, weight loss, the evidence is negative, the FDA position is explicit, and federal enforcement action is a matter of record. A laboratory treating hCG as what it is, a glycoprotein hormone requiring glycoprotein handling and glycoprotein specifications, is on solid ground. One treating it as a peptide in a vial is not.

By [AUTHOR NAME PLACEHOLDER], [CREDENTIALS PLACEHOLDER]. Fact-checked by [FACT-CHECKER NAME PLACEHOLDER].

Research Use Only Disclaimer

Human chorionic gonadotropin and all other compounds discussed in this article are, as supplied to laboratories, intended for laboratory research use only. Research-grade hCG is not an approved drug product: no marketing authorisation, no approved labelling, no approved indication, no regulated manufacturing or sterility standard, no endotoxin specification and no approved route of administration. The existence of approved prescription products containing chorionic gonadotropin or choriogonadotropin alfa confers no regulatory status whatsoever on research-grade material.

Nothing here is medical, veterinary or pharmaceutical advice, and nothing constitutes a dosing recommendation, a protocol for use in humans or animals, or a therapeutic claim of any kind. Research materials described here are not for human or veterinary use. Descriptions of approved indications, labelling statements and enforcement actions summarise the published regulatory record; they are not guidance. There are no FDA-approved hCG products for weight loss.

hCG is prohibited in male athletes at all times under the World Anti-Doping Agency Prohibited List. Bacteriostatic Water for Injection, USP contains benzyl alcohol and is contraindicated in neonates. Readers with clinical questions should consult a qualified healthcare professional, and are responsible for compliance with all applicable laws, institutional review and animal ethics requirements, anti-doping regulations and biosafety rules in their jurisdiction.

Stay updated, free articles. Join our Telegram channel

Join